Immatics N V (IMTX)

Jun 05, 2025

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - mx.advfn.com

Jun 05, 2025

Jun 05, 2025

Immatics rises on data from early stage cell therapy trial - MSN

Jun 05, 2025

Jun 05, 2025

Millennium Management LLC Has $1.11 Million Holdings in Immatics (NASDAQ:IMTX) - Defense World

Jun 05, 2025

Jun 04, 2025

Immatics: Taking Off On A PRAME Rocketship - Seeking Alpha

Jun 04, 2025

Jun 03, 2025

Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect? - Yahoo Finance

Jun 03, 2025

Jun 03, 2025

Immatics Announces Annual General Meeting for June 2025 - TipRanks

Jun 03, 2025

Jun 02, 2025

immatics n.v. announces upcoming annual general meeting By Investing.com - Investing.com South Africa

Jun 02, 2025

Jun 02, 2025

immatics n.v. announces upcoming annual general meeting - Investing.com

Jun 02, 2025

Jun 02, 2025

Immatics (IMTX) Soars After Positive Trial Results for Cell Ther - GuruFocus

Jun 02, 2025

Jun 02, 2025

Cantor Fitzgerald reiterates overweight rating on Immatics stock By Investing.com - Investing.com UK

Jun 02, 2025

Jun 02, 2025

Immatics Presents Promising IMA203 Data at ASCO 2025 - TipRanks

Jun 02, 2025

Jun 02, 2025

Form 6-K Immatics N.V. For: Jun 02 - StreetInsider

Jun 02, 2025

Jun 02, 2025

Northern Trust Corp Purchases 11,304 Shares of Immatics (NASDAQ:IMTX) - Defense World

Jun 02, 2025

Jun 01, 2025

Immatics (IMTX) Shares Promising Data from IMA203 Melanoma Trials | IMTX Stock News - GuruFocus

Jun 01, 2025

May 31, 2025

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 - GlobeNewswire

May 31, 2025

May 31, 2025

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO - GuruFocus

May 31, 2025

May 31, 2025

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | IMTX Stock News - GuruFocus

May 31, 2025

May 31, 2025

Immatics N.V. Reports Promising Long-Term Efficacy and Safety Data from Phase 1b Trial of IMA203 PRAME Cell Therapy in Metastatic Melanoma - Nasdaq

May 31, 2025

May 31, 2025

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma - Yahoo

May 31, 2025

May 31, 2025

Immatics (NASDAQ:IMTX) Receives $17.00 Average Price Target from Analysts - Defense World

May 31, 2025

May 30, 2025

Immatics N.V. (IMTX) Stock Analysis: Uncovering a 163% Upside Potential in the Biotech Arena - DirectorsTalk Interviews

May 30, 2025

May 29, 2025

Long Term Trading Analysis for (IMTX) - news.stocktradersdaily.com

May 29, 2025

May 29, 2025

Immatics (NASDAQ:IMTX) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft - Defense World

May 29, 2025

May 29, 2025

D. E. Shaw & Co. Inc. Has $176,000 Stake in Immatics (NASDAQ:IMTX) - Defense World

May 29, 2025

May 28, 2025

Deutsche Bank Initiates Coverage of Immatics N.V. (IMTX) with Buy Recommendation - Nasdaq

May 28, 2025

May 28, 2025

Immatics (IMTX) Receives "Buy" Rating from Deutsche Bank | IMTX Stock News - GuruFocus

May 28, 2025

May 28, 2025

Deutsche Bank Initiates Coverage on Immatics With Buy Rating, $10 Price Target - marketscreener.com

May 28, 2025

May 28, 2025

Deutsche Bank Gives Immatics (IMTX) a Boost with Buy Rating and $10 Target | IMTX Stock News - GuruFocus

May 28, 2025

May 28, 2025

Deutsche Bank sets $10 target for Immatics stock on Buy rating - Investing.com UK

May 28, 2025

May 18, 2025

Immatics FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World

May 18, 2025

May 17, 2025

Lacklustre Performance Is Driving Immatics N.V.'s (NASDAQ:IMTX) Low P/S - simplywall.st

May 17, 2025

May 16, 2025

The Manufacturers Life Insurance Company Sells 71,487 Shares of Immatics (NASDAQ:IMTX) - Defense World

May 16, 2025

May 15, 2025

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely - Yahoo Finance

May 15, 2025

May 14, 2025

Immatics: Q1 Earnings Snapshot - CT Insider

May 14, 2025

May 14, 2025

Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewswire

May 14, 2025

May 13, 2025

Immatics NV earnings missed by €0.07, revenue topped estimates - Investing.com South Africa

May 13, 2025

May 13, 2025

Immatics NV reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025

May 13, 2025

IMTX Sees Revenue Decline, Highlights Advances in Melanoma Thera - GuruFocus

May 13, 2025

May 13, 2025

Immatics Reports Increased Q1 2025 Loss Amid Rising R&D Costs - TipRanks

May 13, 2025

May 13, 2025

Immatics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025

May 11, 2025

Immatics (IMTX) Projected to Post Quarterly Earnings on Tuesday - Defense World

May 11, 2025

May 09, 2025

IMTXImmatics N.V Latest Stock News & Market Updates - Stock Titan

May 09, 2025

May 09, 2025

(IMTX) Proactive Strategies - news.stocktradersdaily.com

May 09, 2025

Apr 30, 2025

Immatics US opens 100,000-square-foot Stafford cell-therapy manufacturing plant (PHOTOS) - The Business Journals

Apr 30, 2025

Apr 30, 2025

Guggenheim Capital LLC Takes $101,000 Position in Immatics (NASDAQ:IMTX) - Defense World

Apr 30, 2025

Apr 25, 2025

Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co. - Defense World

Apr 25, 2025

Apr 24, 2025

Are Immatics N.V (IMTX) shares a good deal now? - uspostnews.com

Apr 24, 2025

Apr 23, 2025

Immatics Announces Upcoming Oral and Poster Presentation on IMA2 - GuruFocus

Apr 23, 2025